25 Real-Life Examples: How High Valuation Can Hurt Investors, Let Me Count the Ways

Introduction It almost every article I have ever published, I talk about valuation in one manner or another.  So much so, that readers have dubbed me Mr. Valuation.  The primary reason I am so obsessed about valuation is because I believe it is one of the most important and yet mostly ignored and overlooked concepts Read more about 25 Real-Life Examples: How High Valuation Can Hurt Investors, Let Me Count the Ways[…]

Campbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4

Introduction This is the fourth of what will be a long-running series highlighting dividend growth stocks that have technically entered bear market territory.  Many investors define a bear market as when prices fall at least 20%.  After coming out of the true bear market inspired by the Great Recession, stocks have generally been enjoying a Read more about Campbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4[…]

Celgene: Growth At A Reasonable Price Even On Revised Guidance

Introduction This article is an update to my original article on Celgene (CELG) published on June 22, 2017.  Celgene reported their financial results yesterday October 26, 2017, and although the quarter was good, lowered guidance crushed the stock price.  In my opinion, some of the sag in price was justified, but for the most part Read more about Celgene: Growth At A Reasonable Price Even On Revised Guidance[…]